A good year for Biotechnology ETFs

AccuServe uses domestic, specialty ETFs focused on health care/biotechnology to assess how these funds performed and arrive at an overarching trend year-over-year for valuations. 1-year returns of such funds have ranged between 11.6% and 57.4% with a trading volume-weighted average of 25.8% return. Clearly, the valuations have improved significantly. The relatively highly traded (70.7% of trading volume) healthcare sector SPDR's 1-year return increased by a significant 25.43%.